跨国药企扫货中国创新药 谁是首席买家

Core Insights - The article highlights the significant interest of multinational pharmaceutical companies in Chinese assets, particularly in the context of the 2026 JPMorgan Healthcare Conference, indicating a sustained trend in foreign licensing deals for Chinese innovative drugs [2][14]. Group 1: Transaction Activity - AstraZeneca was the most active multinational pharmaceutical company in 2025, engaging in five transactions [4][3]. - Pfizer and Takeda Pharmaceutical also made notable moves, each completing four transactions, with Pfizer's deal with 3SBio setting a record for upfront payments in Chinese innovative drug licensing at $1.25 billion [7][11]. - GSK's collaboration with HengRui Medicine reached a record potential total of $12.5 billion, marking the highest transaction value for Chinese innovative drug licensing [13][14]. Group 2: Financial Commitments - AstraZeneca, GSK, and Takeda signed contracts exceeding $10 billion, while Pfizer and Novartis had contracts over $5 billion [11]. - AstraZeneca's collaboration with CSPC Pharmaceutical, with a potential total transaction value exceeding $5.3 billion, ranked among the top four deals of the year [5]. - The article notes that AstraZeneca's commitment to China remains strong, with a $2.5 billion investment plan announced in early 2025 [5]. Group 3: Market Trends - The total value of licensing deals for Chinese innovative drugs surpassed $130 billion in 2025, with over 150 transactions, accounting for approximately 40% of global activity [2][14]. - The article emphasizes the growing attractiveness of Chinese drugs, with foreign companies from India, Latin America, and the Middle East also showing interest in the Chinese market [7][8]. - The article suggests that the rapid rise of Chinese innovative drugs is perceived as a significant competitive challenge for U.S. counterparts, highlighting the efficiency of Chinese companies in obtaining clinical data [14].